Celecoxib Versus Diclofenac In The Treatment Of Osteoarthritis Of The Hip
Launched by PFIZER · Sep 9, 2005
Trial Information
Current as of July 21, 2025
Completed
Keywords
ClinConnect Summary
No description provided
Gender
ALL
Eligibility criteria
- Inclusion Criteria:
- • Diagnosed with osteoarthritis of hip and requiring joint replacement
- • Eligible for chronic therapy with an NSAID
- Exclusion Criteria:
- • Hip surgery anticipated within 8 calendar weeks after first visit
- • Active gastrointestinal disease or recent diagnosis of gastrointestinal ulceration (within 60 days of first visit)
About Pfizer
Pfizer Inc. is a global leader in biopharmaceutical innovation, dedicated to discovering, developing, and delivering advanced therapies that enhance patient outcomes across a wide range of medical conditions. With a rich history of scientific research and a commitment to quality, Pfizer focuses on areas such as oncology, immunology, cardiology, and rare diseases. The company leverages cutting-edge technology and collaborates with healthcare professionals, regulatory bodies, and academic institutions to conduct rigorous clinical trials that ensure the safety and efficacy of its products. Pfizer's mission is to bring breakthroughs that change patients' lives, exemplifying its commitment to health and wellness worldwide.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
Bradford, , United Kingdom
Edinburgh, , United Kingdom
London, , United Kingdom
Manchester, , United Kingdom
Southampton, , United Kingdom
Northampton, , United Kingdom
Greenisland, Carrickfergus, Northern Ireland, United Kingdom
Harrow, Middlesex, United Kingdom
Peterborough, , United Kingdom
Wansford, , United Kingdom
Westbury, , United Kingdom
Aston Clinton, Bucks, United Kingdom
Ely, Cambs, United Kingdom
St. Austell, Cornwall, United Kingdom
Lancaster, England, United Kingdom
Sheffield, England, United Kingdom
Newport, Gwent, United Kingdom
Chingford, London, United Kingdom
Oxford, Oxon, United Kingdom
Greenock, Renfrewshire, United Kingdom
Barry, South Glamorgan, United Kingdom
Barnsley, South Yorkshire, United Kingdom
Ashford, Surrey, United Kingdom
Newcastle Upon Tyne, Tyne & Wear, United Kingdom
Trowbridge, Wiltshire, United Kingdom
Aberdeen, , United Kingdom
Amersham, , United Kingdom
Bath, , United Kingdom
Belfast, , United Kingdom
Cardiff, , United Kingdom
Carshalton, , United Kingdom
Chertsey, , United Kingdom
Glasgow, , United Kingdom
Leystonstone, London, , United Kingdom
Liverpool, , United Kingdom
Norwich, , United Kingdom
Nuneaton, , United Kingdom
Truro, , United Kingdom
Watford, , United Kingdom
Wigan, , United Kingdom
Newcastle Upon Tyne, , United Kingdom
Patients applied
Trial Officials
Pfizer CT.gov Call Center
Study Director
Pfizer
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported
Similar Trials